Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Non-Current Liabilities (2022 - 2026)

Heron Therapeutics filings provide 5 years of Total Non-Current Liabilities readings, the most recent being $232.2 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 11.91% to $232.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $232.2 million, a 11.91% decrease, with the full-year FY2025 number at $236.7 million, down 11.06% from a year prior.
  • Total Non-Current Liabilities hit $232.2 million in Q1 2026 for Heron Therapeutics, down from $236.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $266.2 million in Q4 2024 to a low of $229.4 million in Q3 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $251.4 million (2024), compared with a mean of $249.5 million.
  • Biggest five-year swings in Total Non-Current Liabilities: grew 8.34% in 2024 and later decreased 11.96% in 2025.
  • Heron Therapeutics' Total Non-Current Liabilities stood at $237.1 million in 2022, then increased by 8.05% to $256.2 million in 2023, then grew by 3.88% to $266.2 million in 2024, then fell by 11.06% to $236.7 million in 2025, then dropped by 1.94% to $232.2 million in 2026.
  • The last three reported values for Total Non-Current Liabilities were $232.2 million (Q1 2026), $236.7 million (Q4 2025), and $229.4 million (Q3 2025) per Business Quant data.